ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
Key Highlights
- ➤Q3 sales $8.0 million, up 46.0% year over year
- ➤Nine-month sales $25.6 million, up 27.8% year over year
- ➤Domestic Q3 sales $6.9 million, up 29.2% year over year
- ➤Tri-Shield Q3 sales grew 51%; Dual-Force increased 36%
- ➤Functional feed line Q3 sales grew 37%
Expert Statements
Timothy Fiori, Chief Financial Officer of ImmuCell
“Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase compared to the three months ended September 30, 2025. Domestic sales were $6.9 million, a 29.2% increase compared to 2025.”
Timothy Fiori, Chief Financial Officer of ImmuCell
“We are pleased with the sales results experienced during the third quarter of 2026, recognizing our comparative sales growth was aided, in part, by depressed sales levels in the third quarter of 2025 caused by high distributor purchases in the second quarter of 2025. Total sales for the nine months ended September 30, 2026 were $25.6 million, a 27.8% increase compared to the nine months ended September 30, 2025.”
Olivier te Boekhorst, President and CEO of ImmuCell
“Our third quarter growth reflects the results of our sales team expansion and continuous improvements in commercial execution,”
Olivier te Boekhorst, President and CEO of ImmuCell
“supported by our improved ability to reliably manufacture product to meet customer demand. Third quarter growth was broad-based across the portfolio, with Tri-Shield( ®) growing at 51% over the third quarter of 2025, Dual-Force( ®) at 36%, and our recently launched functional feed line at 37%.”
PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the third quarter of 2026.
“Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase compared to the three months ended September 30, 2025. Domestic sales were $6.9 million, a 29.2% increase compared to 2025,” said Timothy Fiori, Chief Financial Officer of ImmuCell. “We are pleased with the sales results experienced during the third quarter of 2026, recognizing our comparative sales growth was aided, in part, by depressed sales levels in the third quarter of 2025 caused by high distributor purchases in the second quarter of 2025. Total sales for the nine months ended September 30, 2026 were $25.6 million, a 27.8% increase compared to the nine months ended September 30, 2025.”
Get started
Create a free account to read the full story.